Optimum and its clients push on as summer beckons
It’s May already, and Optimum Strategic Communications and its clients have had their foot on the gas this week as we head into the summer months.
Poolbeg signs exclusive option agreement to acquire orphan drug candidate for Behçet’s Disease
Poolbeg Pharma, a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announced on Tuesday that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc to acquire, for a nominal fee, a novel topical muco-adherent formulation of Pentoxifylline (tPTX) for the treatment of oral ulcers in patients suffering from Behçet’s Disease.
Poolbeg also announced financial results for the year ended 31 December 2023, and has received a fully granted patent in the U.S. for its Immunomodulator II patent application.
SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
SynOx Therapeutics Limited, the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, on Tuesday announced that it has entered into a $35m loan facility with Hercules Capital, Inc.
Based in Dublin and Oxford, SynOx is developing emactuzumab – a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody.
The funding is additional to a recent $75m Series B financing and provides a flexible loan facility to support additional clinical work and activities to drive successful registration and commercialisation.
Scientific leaders gather at global summit in Denmark to advance knowledge and solutions on health and sustainability
Leading scientists, philanthropists, and policymakers from around the world are coming together in Denmark at the Global Science Summit, hosted by the Novo Nordisk Foundation as part of the organisation’s 100-year anniversary. The goal is to explore the interaction between the world’s biggest health and sustainability challenges and pave the way for new scientific breakthroughs.
Speakers at the summit on 6-7 May 2024 include Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization; Mr. Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation; Dr. Catherine Kyobutungi, Executive Director of the African Population and Health Research Center; and Dr. John-Arne Røttingen, CEO of Wellcome.
Novo Holdings invests DKK 1.4 billion (€188 million) in quantum tech start-up ecosystem
Novo Holdings has announced plans to build a quantum technology start-up ecosystem in Denmark, aiming to support and advance some of the world’s most promising quantum technology companies with applications in life sciences.
The quantum industry, which develops novel technologies such as quantum computers or quantum sensing based on quantum physics, holds the potential to dramatically affect a number of industries, and in particular the life sciences. Quantum technologies are currently on a steep development trajectory, especially in the Nordics.
Gudrun Vogtentanz, Chief Scientific Officer at AMSilk, to speak at the Rethinking Materials Summit, 14 May 2024
AMSilk GmbH, a frontrunner in advanced biomaterials made from spider silk-based proteins, on Thursday announced that Gudrun Vogtentanz, Chief Scientific Officer, will participate in a panel discussion titled ‘Advancing the Bioeconomy: Plant-Based Specialty Chemicals and Bio-Based Building Block Molecules’ at the Rethinking Materials Summit in London on the 14th of May.
AMSilk’s spider silk-based protein materials offer high-performance qualities which translate to a wide range of applications in the textile, homecare, biomedical, and automobile industries. Based on their exceptional natural properties, which can be tailored to the specific needs of the market or customer, AMSilk’s high-performance material outweighs many natural or fossil-based materials, while being verifiably biodegradable.
